Prolynx secured $70 million in financing to advance its long‑acting obesity drug platform that uses proprietary linker chemistry to create monthly or quarterly versions of incretin and non‑incretin therapies. The company also recruited Amgen’s obesity commercial lead as CEO, signalling an intent to accelerate clinical development and commercialization planning. Prolynx’s technology focuses on linker and formulation approaches to extend peptide half‑life and dosing intervals. The funding and commercial hire position Prolynx to compete in the long‑acting obesity category, where investors are backing both biotechs and Big Pharma entrants. Sources: financing announcements and company statements.